Membrane fusogenic liposome for tumor targeting and penetration

Abstract

Extracellular vesicles are known as a key factor of inter-cellular signaling pathway and cell differentiation. It has been observed from body fluid such as urine, saliva, ascites, so its physiological roles have been studied actively. Further, extracellular vesicles s study for cancer diagnosis and therapy have been proceeded consistently, because it was reported that Extracellular vesicles are related with inflammation of disease progression, and distant or remote cancer metastasis.

However, there are few weakness to apply extracellular vesicles for cancer diagnosis and treatment. When extracellular vesicles are isolated and purified, extracellular vesicles cannot act as a bio-nanomaterial, because of extracellular vesicles aggregation.

To make up for above defect, in vivo extracellular vesicles engineering via nanoparticles was reported. But the conventional nanoparticles have high clearance rate in vivo Reticulo-Endothelial system (RES) due to surface positive charge for interaction with cell membrane. So we develop H-MFLs which have membrane vesicle engineering through fusion mecha-nism as well as tumor targeting ability and minimized in vivo clearance rate by using target-ing peptide conjugation to liposome surface.

This extracellular vesicle engineering method via H-MFLs can deliver functional mole-cules and anti-cancer drug to interior site of tumor tissues as well as have enhanced drug delivery efficiency, thereby, we can expect much higher therapeutic efficacy. Accordingly, these results show that synthetic nanoparticle mediated drug delivery can deliver chemo-therapeutic agent efficiently to solid tumors and other disease tissues which have existing delivery problem.